Background: Mucormycosis, a fungal infection caused by Rhizopus species is on the rise in COVID-19 patients as a result of their suppressed immunity. The current therapies include systemic administration of Amphotericin B.
Hypothesis and method: We screened several triazole broad-spectrum antifungal agents against the therapeutic target in mucormycosis using computational techniques like molecular docking and compared them with isavuconazole, an approved drug.
Result: The study concluded that 4 triazole drugs, pramiconazole, itraconazole, posaconazole and ketoconazole were strong candidates to be further evaluated and developed as a treatment for mucormycosis.
Conclusion: Novel topical and oral therapies could be developed from these drug leads.
Keywords: Antifungal; Drug repurposing; Molecular docking; Mucormycosis; Triazoles.
Copyright © 2021 Elsevier Ltd. All rights reserved.